FDA Clears Ocugen’s Phase II/III Trial for Stargardt Disease Gene Therapy
Ocugen’s OCU410ST gene therapy gets another green light. Next stop: a Phase II/III trial. The U.S. Food and Drug Administration…
![[Newsroom] Thumbnail GLP1 and AMD Story](https://piemagazine.org/wp-content/uploads/sites/4/2025/06/Newsroom-Thumbnail-GLP1-and-AMD-Story-579x326.png)
GLP-1 Agonists Associated with Doubled Risk of Neovascular AMD, Study Finds
Blockbuster meds, blockbuster risks? Trending GLP-1s (like Ozempic) are now raising red flags for nAMD. A new population-based cohort study…
popular posts
latest posts
